| Biomarker ID | 511 |
| PMID | 20068566 |
| Year | 2010 |
| Biomarker | TMPRSS2–ERG |
| Biomarker Basis | Expression Based (Fusion Based) |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Fusion Positive in Recurrence |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(TMPRSS2):- Androgen receptor regulation of biosynthesis and transcription,Androgen receptor proteolysis and transcription regulation;Pathways Include(ERG):-Genes targeted by miRNAs in adipocytes WP1992,VEGFA-VEGFR2 Signaling Pathway WP3888 |
| Experiment | Biochemical recurrence Vs No recurrence |
| Type of Biomarker | Prognostic |
| Cohort | Total of 139 patients (GSE18655) were chosen for this study out of which 69 were fusion positive and 70 were fusion negative and 33 experienced biochemical recurrence. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.0000000354 |
| Method Used | cDNA mediated , annealing, selection, extension and litigation (DASL) |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Dataset |
| Technical Name | TMPRSS2, ERG |